Clinical Trial Update: Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 trial of AMG 420 in relapsed and/or refractory multiple myeloma was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• AMG 420

Snippet

Sponsor: Amgen | Conditions: Relapsed and/or Refractory Multiple Myeloma | Phase 1 | Status: TERMINATED | Results posted: 2024-01-05